- Author
- Francis Combes (UGent) , Evelyne Meyer (UGent) and Niek Sanders (UGent)
- Organization
- Abstract
- This review article describes the use of immune cells as potential candidates to deliver anti-cancer drugs deep within the tumor microenvironment. First, the rationale of using drug carriers to target tumors and potentially decrease drug-related side effects is discussed. We further explain some of the current limitations when using nanoparticles for this purpose. Next, a comprehensive step-by-step description of the migration cascade of immune cells is provided as well as arguments on why immune cells can be used to address some of the limitations associated with nanoparticle-mediated drug delivery. We then describe the benefits and drawbacks of using red blood cells, platelets, granulocytes, monocytes, macrophages, myeloid-derived suppressor cells, T cells and NK cells for tumor-targeted drug delivery. An additional section discusses the versatility of nanoparticles to load anti-cancer drugs into immune cells. Lastly, we propose increasing the circulatory half-life and development of conditional release strategies as the two main future pillars to improve the efficacy of immune cell-mediated drug delivery to tumors.
- Keywords
- Pharmaceutical Science, NATURAL-KILLER-CELLS, RED-BLOOD-CELLS, TISSUE-RESIDENT MACROPHAGES, METASTATIC BREAST-CANCER, IN-VIVO, T-CELLS, SUPPRESSOR-CELLS, BONE-MARROW, NEUTROPHIL RECRUITMENT, GENE-THERAPY, Targeted drug delivery, Immune cells, Tumor microenvironment, Circulatory half-life, Conditional release
Downloads
-
NS - Combes et al. review JCR 2020.pdf
- full text (Published version)
- |
- open access
- |
- |
- 2.05 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8702820
- MLA
- Combes, Francis, et al. “Immune Cells as Tumor Drug Delivery Vehicles.” JOURNAL OF CONTROLLED RELEASE, vol. 327, 2020, pp. 70–87, doi:10.1016/j.jconrel.2020.07.043.
- APA
- Combes, F., Meyer, E., & Sanders, N. (2020). Immune cells as tumor drug delivery vehicles. JOURNAL OF CONTROLLED RELEASE, 327, 70–87. https://doi.org/10.1016/j.jconrel.2020.07.043
- Chicago author-date
- Combes, Francis, Evelyne Meyer, and Niek Sanders. 2020. “Immune Cells as Tumor Drug Delivery Vehicles.” JOURNAL OF CONTROLLED RELEASE 327: 70–87. https://doi.org/10.1016/j.jconrel.2020.07.043.
- Chicago author-date (all authors)
- Combes, Francis, Evelyne Meyer, and Niek Sanders. 2020. “Immune Cells as Tumor Drug Delivery Vehicles.” JOURNAL OF CONTROLLED RELEASE 327: 70–87. doi:10.1016/j.jconrel.2020.07.043.
- Vancouver
- 1.Combes F, Meyer E, Sanders N. Immune cells as tumor drug delivery vehicles. JOURNAL OF CONTROLLED RELEASE. 2020;327:70–87.
- IEEE
- [1]F. Combes, E. Meyer, and N. Sanders, “Immune cells as tumor drug delivery vehicles,” JOURNAL OF CONTROLLED RELEASE, vol. 327, pp. 70–87, 2020.
@article{8702820,
abstract = {{This review article describes the use of immune cells as potential candidates to deliver anti-cancer drugs deep within the tumor microenvironment. First, the rationale of using drug carriers to target tumors and potentially decrease drug-related side effects is discussed. We further explain some of the current limitations when using nanoparticles for this purpose. Next, a comprehensive step-by-step description of the migration cascade of immune cells is provided as well as arguments on why immune cells can be used to address some of the limitations associated with nanoparticle-mediated drug delivery. We then describe the benefits and drawbacks of using red blood cells, platelets, granulocytes, monocytes, macrophages, myeloid-derived suppressor cells, T cells and NK cells for tumor-targeted drug delivery. An additional section discusses the versatility of nanoparticles to load anti-cancer drugs into immune cells. Lastly, we propose increasing the circulatory half-life and development of conditional release strategies as the two main future pillars to improve the efficacy of immune cell-mediated drug delivery to tumors.}},
author = {{Combes, Francis and Meyer, Evelyne and Sanders, Niek}},
issn = {{0168-3659}},
journal = {{JOURNAL OF CONTROLLED RELEASE}},
keywords = {{Pharmaceutical Science,NATURAL-KILLER-CELLS,RED-BLOOD-CELLS,TISSUE-RESIDENT MACROPHAGES,METASTATIC BREAST-CANCER,IN-VIVO,T-CELLS,SUPPRESSOR-CELLS,BONE-MARROW,NEUTROPHIL RECRUITMENT,GENE-THERAPY,Targeted drug delivery,Immune cells,Tumor microenvironment,Circulatory half-life,Conditional release}},
language = {{eng}},
pages = {{70--87}},
title = {{Immune cells as tumor drug delivery vehicles}},
url = {{http://doi.org/10.1016/j.jconrel.2020.07.043}},
volume = {{327}},
year = {{2020}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: